Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: John F Beule who wrote (790)	12/22/1998 8:48:00 AM
From: John F Beule	Read Replies (1) \| Respond to of 2539

Major Changes in the Treatment of Osteoporosis, Rheumatoid Arthritis, andRelated Diseases Lie Ahead, According to a Decision Resources Report WALTHAM, Mass., Dec 18 /PRNewswire/ -- The Outlook for Bone and Connective Tissue Disease Therapy Markets, a new DR Report from Decision Resources, is a timely study that discusses new approaches to treating a broad range of bone and connective tissue diseases, and their potential impact on sales in their relevant therapeutic group. We predict the following developments: -- Direct sales of drugs to treat bone and connective tissue diseases will reach $25 billion annually by 2007. -- Improved COX-2-specific NSAIDs such as celebrex (celecoxib) from Searle and rofecoxib (vioxx) from Merck will likely be launched in 1999 and 2000, respectively. These NSAIDs are designed to relieve pain and inflammation in autoimmune diseases and osteoarthritis with reduced GI side effects. In 2001 we will see the launch of NSAIDs with a more potent analgesic effect -- eltanac from Byk Gulden and tinoprofen from Japan Tobacco. -- An increasing commitment to identify genomic aberrations and translate the findings into new approaches for diagnosis and therapy. -- Commercial development of TNF antagonists for severe rheumatoid arthritis will continue to be focused on drugs such as Immunex's Enbrel (etanercept) that antagonize the action of the cytokines rather than chemokines. -- We expect a steady convergence of therapies that are used for a variety of autoimmune diseases and which have the same basic origin of immune system dysfunction. As the convergence plays out, certain drugs found to be multi-indicational will see dramatic sales growth potential. This hypothesis is well illustrated in the case of Arava (Hoechst Marion Roussel), recently approved for rheumatoid arthritis and now in clinical trials for lupus. -- The use of immunosuppressive drugs (predominantly methotrexate and cyclophosphamide) for control over the progression of autoimmune disease will increase significantly during the next decade. Journalists, contact: Cindy Corona, phone 781-487-3721, e-mail corona@dresources.com. Sales inquiries, contact: Jean Carbone, phone 781-487-3737, e-mail drreports@dresources.com. This report is available for $3200.00. DR Reports analyze technological advances, regulatory developments, and business trends in the health care industry. Decision Resources was founded as a subsidiary of Arthur D. Little, Inc., and is now an independent, employee-owned health care research and consulting firm. SOURCE Decision Resources CO: Decision Resources ST: Massachusetts IN: MTC SU: 12/18/98 09:47 EST prnewswire.com